Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase
about
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsPreclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationFGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical SignaturesThe 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognitionDesign, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffoldFibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell CancersInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationRedefining Cheminformatics with Intuitive Collaborative Mobile AppsTransforming fusions of FGFR and TACC genes in human glioblastoma.Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Drug-sensitive FGFR3 mutations in lung adenocarcinoma.Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLCEndothelial cell FGF signaling is required for injury response but not for vascular homeostasis.Development and experimental test of support vector machines virtual screening method for searching Src inhibitors from large compound libraries.The FGF/FGFR axis as a therapeutic target in breast cancer.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumorsSynthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapyFGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation.Fibroblast Growth Factor Receptors (FGFRs) in Human Sperm: Expression, Functionality and Involvement in Motility RegulationCombinatorial Pharmacophore-Based 3D-QSAR Analysis and Virtual Screening of FGFR1 Inhibitors.FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal CarcinomaCrystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.Palladium-catalyzed cross-coupling of aryl chlorides and triflates with sodium cyanate: a practical synthesis of unsymmetrical ureas.Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in CholangiocarcinomaTyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase InhibitorsA combinatorial strategy for treating KRAS-mutant lung cancerInhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinomaTrichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo
P2860
Q26801718-2853DA46-0B1D-4BF9-A325-07BD0BCC1545Q27322795-B7C89771-1F0C-48E6-A89F-35A1928CBAA0Q27684227-7C7F2D3F-03A0-469C-ACD9-9EB75FE532F1Q27698320-4AC2E4E5-C777-43B4-B70E-9A24CDCD1931Q27701029-D77C59A2-5867-4B3C-B0BC-9CADDB9927D2Q27852581-CB82018D-10B6-4A73-AA4E-B8970D7C1489Q27853061-15AC2B82-082F-458B-8ABF-94E770A4A474Q27853171-20BC8808-A95E-4239-9A34-C3197C7F4C51Q28079309-87D012C2-75D6-462C-8F78-309322F8B88DQ28710562-D166E204-35F6-4C69-8E3B-2A17FC7A58F7Q30540467-055223DF-F9B9-4EFE-A889-58D19530EB01Q30857433-1D3126E6-F257-4507-A9F2-2C4A91647DC6Q33564782-6DC31AC3-4FEA-4D24-B5A4-E7425D2776A9Q33688625-71839C38-B76F-479C-8726-7C49D861838CQ33751398-8F13CCFB-B8ED-43D9-BBDE-14510E34E781Q34135320-8CDEC7C0-4525-4748-9CB6-0B668A1281C7Q34218313-E3B274B4-B949-4F14-8CAF-2B167B3DE0DEQ34485998-DD13AD04-2C62-4918-8E3F-2C9C995598ADQ34495216-991A7704-B2B8-4992-A6B3-92CD14AD6E5AQ34525925-D8634A5F-400C-4F38-BF97-E9B93AC812B6Q34611953-54E0A58F-494B-41B7-B043-726735CF0B9BQ35035462-F441001E-7753-4E48-91BC-099DFB5A6D9BQ35129076-B155D6C1-74CA-4E38-8C3D-26E77669E40FQ35253119-B7F8CDDA-4973-4344-B4B0-FF424307651DQ35602057-938C7B19-4D98-4FCC-A6FB-43D16E3C7532Q35814029-4D8B1287-B288-47BD-AEFD-4581B572D6E3Q35837391-C2E17F26-230C-4840-B2A6-A20222BBB535Q36129968-DB266E4D-EC22-4679-9797-18A4BB14E7E5Q36298492-3AC082C7-4546-4115-9691-05413D43594AQ36320551-C3FA7822-FFE7-44C7-90C5-9AC48D47DE7EQ36392523-286E5CC3-0BBE-4671-B238-AD8AAE9011F3Q36685324-90054240-E5F5-4E84-B92C-9ED1C18F3C3FQ36778814-8F3928DB-93E6-4CC8-B9DC-853EA387D671Q36867279-C9D57FCF-14C2-4F83-9DF0-395D02DF8B6AQ36885181-F820C550-342A-4D98-A8F5-07F1D6D20C5AQ36903398-BD1916EC-CA85-4C19-B989-FCF69AC4929DQ36996290-17C85A51-C914-4093-9D84-4C0A80105A7EQ37080881-83794FAF-1555-439E-9CC5-2D42520486E8Q37111609-1D42B924-7D37-490B-851F-69499F900170Q37295668-2AECF161-BE74-408C-8CE1-22ADE7EBE256
P2860
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@ast
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@en
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@nl
type
label
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@ast
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@en
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@nl
prefLabel
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@ast
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@en
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@nl
P2093
P3181
P356
P1476
Discovery of 3-(2,6-dichloro-3 ...... ly of receptor tyrosine kinase
@en
P2093
Alfred Zimmerlin
Carsten Spanka
Christelle Stamm
Christian Schnell
Diana Graus Porta
Dirksen Bussiere
Herbert Schmid
Jeremy Murray
Joerg Berghausen
Josef Brueggen
P304
P3181
P356
10.1021/JM2006222
P407
P577
2011-10-27T00:00:00Z